Want to see AU:IMR full AI Analyst Report?
Total Valuation
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh has a market cap or net worth of AU$703.45M. The enterprise value is AU$579.50.
Market CapAU$703.45M
Enterprise ValueAU$579.50
Share Statistics
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh has 353,490,970 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding353,490,970
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s return on equity (ROE) is -2.27 and return on invested capital (ROIC) is -58.28%.
Return on Equity (ROE)-2.27
Return on Assets (ROA)-0.57
Return on Invested Capital (ROIC)-58.28%
Return on Capital Employed (ROCE)-0.83
Revenue Per Employee3.88K
Profits Per Employee-335.92K
Employee Count78
Asset Turnover<0.01
Inventory Turnover2.19
Valuation Ratios
The current PE Ratio of Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh is ―. Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s PEG ratio is 0.35.
PE Ratio―
PS Ratio1042.05
PB Ratio27.34
Price to Fair Value27.34
Price to FCF-15.61
Price to Operating Cash Flow-32.69
PEG Ratio0.35
Income Statement
In the last 12 months, Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh had revenue of 302.50K and earned -26.20M in profits. Earnings per share was -0.09.
Revenue302.50K
Gross Profit-2.10M
Operating Income-23.59M
Pretax Income-26.20M
Net Income-26.20M
EBITDA-22.56M
Earnings Per Share (EPS)-0.09
Cash Flow
In the last 12 months, operating cash flow was -14.40M and capital expenditures -311.64K, giving a free cash flow of -14.71M billion.
Operating Cash Flow-14.40M
Free Cash Flow-14.71M
Free Cash Flow per Share-0.04
Dividends & Yields
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.90
52-Week Price Change52.21%
50-Day Moving Average1.86
200-Day Moving Average1.79
Relative Strength Index (RSI)61.05
Average Volume (3m)287.54K
Important Dates
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh upcoming earnings date is Feb 24, 2027, After Close (Confirmed).
Last Earnings DateAug 9, 2026
Next Earnings DateFeb 24, 2027
Ex-Dividend Date―
Financial Position
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh as a current ratio of 2.47, with Debt / Equity ratio of 225.18%
Current Ratio2.47
Quick Ratio2.41
Debt to Market Cap0.08
Net Debt to EBITDA-0.29
Interest Coverage Ratio-5.47K
Taxes
In the past 12 months, Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh EV to EBITDA ratio is -14.26, with an EV/FCF ratio of -15.93.
EV to Sales1.06K
EV to EBITDA-14.26
EV to Free Cash Flow-15.93
EV to Operating Cash Flow-16.29
Balance Sheet
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh has AU$40.81M in cash and marketable securities with AU$25.97M in debt, giving a net cash position of AU$14.84M billion.
Cash & Marketable SecuritiesAU$40.81M
Total DebtAU$25.97M
Net CashAU$14.84M
Net Cash Per ShareAU$0.04
Tangible Book Value Per ShareAU$0.04
Margins
Gross margin is -895.69%, with operating margin of -7796.89%, and net profit margin of -8661.59%.
Gross Margin-895.69%
Operating Margin-7796.89%
Pretax Margin-8661.59%
Net Profit Margin-8661.59%
EBITDA Margin-7456.40%
EBIT Margin-7796.89%
Analyst Forecast
The average price target for Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh is AU$2.84, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetAU$2.84
Price Target Upside48.09% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast-68.64%
EPS Growth Forecast36.40%